Surface Oncology Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Surface Oncology are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Surface Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Surface Oncology is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 57.6 M | |
| Free Cash Flow | -60 M |
Surface |
Surface Oncology Relative Risk vs. Return Landscape
If you would invest (100.00) in Surface Oncology on April 23, 2025 and sell it today you would earn a total of 100.00 from holding Surface Oncology or generate -100.0% return on investment over 90 days. Surface Oncology is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Surface, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Surface Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Surface Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Surface Oncology, and traders can use it to determine the average amount a Surface Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SURF |
Based on monthly moving average Surface Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Surface Oncology by adding Surface Oncology to a well-diversified portfolio.
Surface Oncology Fundamentals Growth
Surface Stock prices reflect investors' perceptions of the future prospects and financial health of Surface Oncology, and Surface Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Surface Stock performance.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 60.82 M | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 30 M | |||
| EBITDA | (61.87 M) | |||
| Cash And Equivalents | 156.65 M | |||
| Cash Per Share | 2.70 X | |||
| Total Debt | 56.04 M | |||
| Debt To Equity | 0.45 % | |||
| Book Value Per Share | 0.81 X | |||
| Cash Flow From Operations | (59.55 M) | |||
| Earnings Per Share | (1.66) X | |||
| Total Asset | 159.91 M | |||
| Retained Earnings | (204.33 M) | |||
| Current Asset | 22 K | |||
| Current Liabilities | 36 K | |||
Things to note about Surface Oncology performance evaluation
Checking the ongoing alerts about Surface Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Surface Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Surface Oncology is not yet fully synchronised with the market data | |
| Surface Oncology has some characteristics of a very speculative penny stock | |
| Surface Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30 M. Net Loss for the year was (63.59 M) with loss before overhead, payroll, taxes, and interest of (37 M). | |
| Surface Oncology currently holds about 156.65 M in cash with (59.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.7. |
- Analyzing Surface Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Surface Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Surface Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Surface Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Surface Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Surface Oncology's stock. These opinions can provide insight into Surface Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |